5 Jefferies Group UroGen Pharma Trades
Jefferies Group acquired 2.2M UroGen Pharma shares worth $58.9M. That's 0.68% of their equity portfolio (28th largest holding). The investor owns 4.50% of the outstanding UroGen Pharma stock. The first UroGen Pharma trade was made in Q1 2024. Since then Jefferies Group bought shares three more times and sold shares on one occasions. The stake costed the investor $27M, netting the investor a gain of 118% so far.
Avg closing price
Price range
Increased shares by 169.9% (+1.38M shares)
Q2 2025
Avg closing price
$9.61
Price range
$3.93
-
$14.87
Sold 15.6% shares (-151k shares)
Q1 2025
Avg closing price
$10.66
Price range
$9.27
-
$12.13
Increased shares by 0.1% (+929 shares)
Q4 2024
Avg closing price
$11.95
Price range
$10.52
-
$13.11
Increased shares by 14.9% (+125k shares)
Q2 2024
Avg closing price
$14.22
Price range
$12.72
-
$19.20
New holding (+840k shares)
Q1 2024
Avg closing price
$16.35
Price range
$13.81
-
$19.33
